Inhibition of heat shock protein 90 attenuates post‑angioplasty intimal hyperplasia

Kassem,Mohammed  M.; Muqri,Furqan; Dacosta,Mary; Bruch,David; Gahtan,Vivian; Maier,Kristopher  G.

doi:10.3892/mmr.2020.10994

Inhibition of heat shock protein 90 attenuates post‑angioplasty intimal hyperplasia

Authors:
- Mohammed M. Kassem
- Furqan Muqri
- Mary Dacosta
- David Bruch
- Vivian Gahtan
- Kristopher G. Maier
View Affiliations

Affiliations: Department of Surgery, Division of Vascular Surgery and Endovascular Services, SUNY Upstate Medical University, Syracuse, NY 13210, USA, College of Medicine, MD Program, SUNY Upstate Medical University, Syracuse, NY 13210, USA
Published online on: February 20, 2020 https://doi.org/10.3892/mmr.2020.10994
Pages: 1959-1964

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intimal hyperplasia (IH) is a pathologic process that leads to restenosis after treatment for peripheral arterial disease. Heat shock protein 90 (HSP90) is a molecular chaperone that regulates protein maturation. Activation of HSP90 results in increased cell migration and proliferation. 17‑N‑allylamino‑17‑demethoxygeldanamycin (17‑AAG) and 17‑dimethylaminoethylamino‑17‑demethoxygeldanamycin (17‑DMAG) are low toxicity Food and Drug Association approved HSP90 inhibitors. The current study hypothesized that HSP90 inhibition was predicted to reduce vascular smooth muscle cell (VSMC) migration and proliferation. In addition, localized HSP90 inhibition may inhibit post‑angioplasty IH formation. For proliferation, VSMCs were treated with serum‑free media (SFM), 17‑DMAG or 17‑AAG. The selected proliferative agents were SFM, platelet derived growth factor (PDGF) or fibronectin. After three days, proliferation was measured. For migration, VSMCs were treated with SFM, 17‑AAG or 17‑DMAG with SFM, PDGF or fibronectin as chemoattractants. Balloon injury to the carotid artery was performed in rats. The groups included in the present study were the control, saline control, 17‑DMAG in 20% pluronic gel delivered topically to the adventitia or intraluminal delivery of 17‑DMAG. After 14 days, arteries were fixed and sectioned for morphometric analysis. Data was analyzed using ANOVA or a student's t‑test. P<0.05 was considered to indicate a statistically significant difference. The results revealed that 17‑AAG and 17‑DMAG had no effect on cell viability. PDGF and fibronectin also increased VSMC proliferation and migration. Furthermore, both 17‑AAG and 17‑DMAG decreased cell migration and proliferation in all agonists. Topical adventitial treatment with 17‑DMAG after balloon arterial injury reduced IH. HSP90 inhibitors suppressed VSMC proliferation and migration without affecting cell viability. Topical treatment with a HSP90 inhibitor (DMAG) decreased IH formation after arterial injury. It was concluded that 17‑DMAG may be utilized as an effective therapy to prevent restenosis after revascularization.

View Figures

View References

1	Valentine RJ, Grayburn PA, Eichhorn EJ, Myers SI and Clagett GP: Coronary artery disease is highly prevalent among patients with premature peripheral vascular disease. J Vasc Surg. 19:668–674. 1994. View Article : Google Scholar : PubMed/NCBI
2	McDivitt JD, Braun M and Kassop D: Cardiovascular disease: Lower extremity peripheral artery disease. FP Essent. 479:11–15. 2019.PubMed/NCBI
3	Asakura Y, Suzuki M, Nonogi H, Haze K, Sato A, Inada H, Okuda Y, Yamashita K and Harano Y: Restenosis after percutaneous transluminal coronary angioplasty in patients with non-insulin-dependent diabetes mellitus (NIDDM). J Cardiovasc Risk. 5:331–334. 1998. View Article : Google Scholar : PubMed/NCBI
4	Goel SA, Guo LW, Liu B and Kent KC: Mechanisms of post- intervention arterial remodelling. Cardiovasc Res. 96:363–371. 2012. View Article : Google Scholar : PubMed/NCBI
5	Weintraub WS: The pathophysiology and burden of restenosis. Am J Cardiol. 100:3K–9K. 2007. View Article : Google Scholar : PubMed/NCBI
6	Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K and Deckmyn H: Platelets at work in primary hemostasis. Blood Rev. 25:155–167. 2011. View Article : Google Scholar : PubMed/NCBI
7	Hoel AW, Yu P, Nguyen KP, Sui X, Plescia J, Altieri DC and Conte MS: Mitochondrial heat shock protein-90 modulates vascular smooth muscle cell survival and the vascular injury response in vivo. Am J Pathol. 181:1151–1157. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, Dionigi G and Roukos DH: The role of heat shock proteins in cancer. Cancer Lett. 360:114–118. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kim J, Jang SW, Park E, Oh M, Park S and Ko J: The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis. J Mol Cell Cardiol. 72:157–167. 2014. View Article : Google Scholar : PubMed/NCBI
10	Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK and Stoeltzing O: Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 6:1123–1132. 2007. View Article : Google Scholar : PubMed/NCBI
11	Hermane J, Eichner S, Mancuso L, Schröder B, Sasse F, Zeilinger C and Kirschning A: New geldanamycin derivatives with anti Hsp properties by mutasynthesis. Org Biomol Chem. 17:5269–5278. 2019. View Article : Google Scholar : PubMed/NCBI
12	Mellatyar H, Talaei S, Pilehvar-Soltanahmadi Y, Barzegar A, Akbarzadeh A, Shahabi A, Barekati-Mowahed M and Zarghami N: Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art. Biomed Pharmacother. 102:608–617. 2018. View Article : Google Scholar : PubMed/NCBI
13	Sausville EA, Tomaszewski JE and Ivy P: Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets. 3:377–383. 2003. View Article : Google Scholar : PubMed/NCBI
14	Jiang D, Zhuang J, Peng W, Lu Y, Liu H, Zhao Q, Chi C, Li X, Zhu G, Xu X, et al: Phospholipase Cγ1 mediates intima formation through Akt-Notch1 signaling independent of the phospholipase activity. J Am Heart Assoc. 6:2017. View Article : Google Scholar
15	Collins TC, Beyth RJ, Nelson DB, Petersen NJ, Suarez- Almazor ME, Bush RL, Hirsch AT and Ashton CM: Process of care and outcomes in patients with peripheral arterial disease. J Gen Intern Med. 22:942–948. 2007. View Article : Google Scholar : PubMed/NCBI
16	Schillinger M and Minar E: Restenosis after percutaneous angioplasty: The role of vascular inflammation. Vasc Health Risk Manag. 1:73–78. 2005. View Article : Google Scholar : PubMed/NCBI
17	Xu Q, Metzler B, Jahangiri M and Mandal K: Molecular chaperones and heat shock proteins in atherosclerosis. Am J Physiol Heart Circ Physiol. 302:H506–H514. 2012. View Article : Google Scholar : PubMed/NCBI
18	Madrigal-Matute J, López-Franco O, Blanco-Colio LM, Muñoz-García B, Ramos-Mozo P, Ortega L, Egido J and Martín-Ventura JL: Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. Cardiovasc Res. 86:330–337. 2010. View Article : Google Scholar : PubMed/NCBI
19	Mayer MP: Gymnastics of molecular chaperones. Mol Cell. 39:321–331. 2010. View Article : Google Scholar : PubMed/NCBI
20	Pearl LH and Prodromou C: Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem. 75:271–294. 2006. View Article : Google Scholar : PubMed/NCBI
21	Mjahed H, Girodon F, Fontenay M and Garrido C: Heat shock proteins in hematopoietic malignancies. Exp Cell Res. 318:1946–1958. 2012. View Article : Google Scholar : PubMed/NCBI
22	Helkin A, Maier KG and Gahtan V: Thrombospondin-1, −2 and −5 have differential effects on vascular smooth muscle cell physiology. Biochem Biophys Res Commun. 464:1022–1027. 2015. View Article : Google Scholar : PubMed/NCBI
23	Doran AC, Meller N and McNamara CA: Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 28:812–819. 2008. View Article : Google Scholar : PubMed/NCBI
24	Liu DH, Yuan HY, Cao CY, Gao ZP, Zhu BY, Huang HL and Liao DF: Heat shock protein 90 acts as a molecular chaperone in late-phase activation of extracellular signal-regulated kinase 1/2 stimulated by oxidative stress in vascular smooth muscle cells. Acta Pharmacol Sin. 28:1907–1913. 2007. View Article : Google Scholar : PubMed/NCBI
25	Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils- Bonnet S, Boilet-Molez S, Potus F, Meloche J, Chabot S, Lambert C, et al: Mitochondrial HSP90 accumulation promotes vascular remodeling in pulmonary arterial hypertension. Am J Respir Crit Care Med. 198:90–103. 2018. View Article : Google Scholar : PubMed/NCBI
26	Wang GK, Li SH, Zhao ZM, Liu SX, Zhang GX, Yang F, Wang Y, Wu F, Zhao XX and Xu ZY: Inhibition of heat shock protein 90 improves pulmonary arteriole remodeling in pulmonary arterial hypertension. Oncotarget. 7:54263–54273. 2016.PubMed/NCBI
27	Li YP, Chen JJ, Shen JJ, Cui J, Wu LZ, Wang Z and Li ZR: Synthesis and biological evaluation of geldanamycin analogs against human cancer cells. Cancer Chemother Pharmacol. 75:773–782. 2015. View Article : Google Scholar : PubMed/NCBI
28	Supko JG, Hickman RL, Grever MR and Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 36:305–315. 1995. View Article : Google Scholar : PubMed/NCBI
29	Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM and Eiseman JL: Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol. 49:7–19. 2002. View Article : Google Scholar : PubMed/NCBI